| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5181f7bc41146d952cf4e72f866a39ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce3d57a6fc2fad533ce367f648d280ec |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 |
| filingDate |
2012-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c620929b8360b11f32ecdee0fdd4a90 |
| publicationDate |
2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012111774-A |
| titleOfInvention |
Treatment of amyotrophic lateral sclerosis |
| abstract |
A therapeutic method for motor neuron disease, more specifically, a therapeutic method for amyotrophic lateral sclerosis (ALS). A method of inducing significant motor performance and increased survival time of an animal by intracerebroventricular delivery of a small amount of vascular endothelial growth factor to a preclinical ALS animal model. Vascular endothelial growth factor is administered intrathecally or intraventricularly. Furthermore, the continuous administration of the factor takes place via an implanted osmotic minipump. The factor is administered at a dose in the range of 0.05-1 μg / kg / day. [Selection figure] None |
| priorityDate |
2004-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |